Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Prevention of hepatic encephalopathy Clinical criteria: Treatment criteria: Must be treated by a gastroenterologist or hepatologist or in consultation with a gastroenterologist or hepatologist. The treatment must be in combination with lactulose, if lactulose is tolerated, AND Patient must have had prior episodes of hepatic encephalopathy.
“Rifaximin acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase resulting in inhibition of bacterial RNA synthesis.”
“6 hours”
“In vitro studies have shown that rifaximin did not inhibit cytochrome P450 isozymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and CYP3A4 at concentrations up to 200 ng/mL (at least 10 times the clinical Cmax).”
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.